Route of Administration for LMWH in Cerebral Venous Thrombosis

Evidence-Based Recommendations

The American College of Cardiology recommends LMWH over unfractionated heparin for the treatment of venous thromboembolism, including cerebral venous thrombosis, with a grade 2C recommendation 1, 2
The standard administration method for LMWH in the treatment of thrombotic disorders is subcutaneous, as indicated in treatment guidelines 1, 3
FDA-approved LMWHs, such as enoxaparin and dalteparin, are specifically formulated for subcutaneous administration, as recommended by the American Heart Association 1, 2

The recommended dose of enoxaparin is 1 mg/kg subcutaneously twice daily or 1.5 mg/kg subcutaneously once daily, as suggested by the American College of Chest Physicians 1, 3
The recommended dose of dalteparin is 200 IU/kg subcutaneously once daily, as recommended by the American College of Cardiology 1, 3
Once daily injection is preferred to twice daily injections, with a grade 2C recommendation, though for large thrombotic burdens, twice daily dosing may be considered 3

Subcutaneous administration of LMWH facilitates outpatient treatment, as recommended by the National Comprehensive Cancer Network 4
Subcutaneous LMWH eliminates the need for therapeutic monitoring in most patients, as suggested by the American College of Cardiology 4
Subcutaneous LMWH has a lower risk of heparin-induced thrombocytopenia compared to unfractionated heparin, with a grade 2C recommendation 1, 3

For patients with severe renal insufficiency, caution is advised due to potential LMWH accumulation, as recommended by the American College of Cardiology 1, 4
In patients with renal impairment, specific dosing adjustments may be required, such as enoxaparin 30 mg subcutaneously daily for prophylaxis and 1 mg/kg subcutaneously every 24 hours for treatment, as suggested by the National Comprehensive Cancer Network 4
LMWH should overlap with warfarin initiation for a minimum of 5 days or until the INR exceeds 2.0 for at least 24 hours, with a grade 1B recommendation 3

Administering LMWH intravenously is not the standard route for this medication, as recommended by the American College of Cardiology 1, 3
Failing to adjust dosing in patients with severe renal impairment is a common pitfall, as suggested by the National Comprehensive Cancer Network 4
Not monitoring platelet counts in high-risk patients is a common pitfall, though routine monitoring is not indicated for most patients on LMWH, as recommended by the American College of Chest Physicians 3